Base de dados : MEDLINE
Pesquisa : D20.215.721.500.490 [Categoria DeCS]
Referências encontradas : 308 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 31 ir para página                         

  1 / 308 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28483499
[Au] Autor:van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
[Ad] Endereço:Cancer Center Amsterdam, Department of Gastroenterology and Hepatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
[Ti] Título:Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
[So] Source:Gastroenterology;153(2):439-447.e2, 2017 Aug.
[Is] ISSN:1528-0012
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Among subjects screened for colorectal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55% of the subjects. Data are limited on how many persons screened by fecal immunochemical tests (FIT), over multiple rounds, develop interval cancers. In the Netherlands, a pilot FIT-based biennial CRC screening program was conducted between 2006 and 2014. We collected and analyzed data from the program on CRCs detected during screening (SD-CRC) and CRCs not detected within the screening program (non-SD-CRC; such as FIT interval cancers, colonoscopy interval cancers, and cancer in nonparticipants). METHODS: Screenees with a negative FIT result received a letter explaining that no blood had been detected in the stool sample and were re-invited, if eligible, for screening biennially. Screenees with a positive FIT result (hemoglobin concentration of 10 µg Hb/g feces) were invited for consultation and scheduled for colonoscopy; results were collected. After the fourth round of FIT screening, the cohort was linked to the Netherlands Cancer Registry, through March 31, 2015; participant characteristics, data on tumor stage, location (at time of resection), and survival status were collected for all identified CRC cases. A reference group comprised all persons with CRC diagnosed in the Netherlands general population during the same period, in the same age range (50-76 years), who had not been offered CRC screening. The median time between invitations (2.37 years) was used as a cutoff to categorize participants within the FIT interval cancer category. We compared participant characteristics, tumor characteristics, and mortality among subjects with SD-CRC and with non-SD-CRC. RESULTS: A total of 27,304 eligible individuals were invited for FIT screening, of whom 18,716 (69%) participated at least once. Of these, 3005 (16%) had a positive result from the FIT in 1 of the 4 screening rounds. In total, CRC was detected in 261 participants: 116 SD-CRCs and 145 non-SD-CRCs (27 FIT interval cancers, 9 colonoscopy interval cancers, and 109 CRCs in nonparticipants). The FIT interval cancer proportion after 3 completed screening rounds was 23%. Participants with SD-CRC had more early-stage tumors than participants with non-SD-CRCs (P < .001). Of persons with SD-CRC and FIT interval cancers, significantly higher proportions survived (89% and 81%, respectively) compared with persons with colonoscopy interval cancers (44% survival) and nonparticipants with CRC (60% survival) (P < .001). CONCLUSIONS: In an analysis of data from a pilot FIT-based biennial screening program, we found that among persons screened by FIT, 23% developed FIT interval cancer. FIT therefore detects CRC with 77% sensitivity. The proportion of FIT interval cancers in FIT screening appears to be lower than that with guaiac fecal occult blood testing. Clinical trial registry: yes, www.trialregister.nl, trial number: NTR5385.
[Mh] Termos MeSH primário: Neoplasias Colorretais/epidemiologia
Detecção Precoce de Câncer/estatística & dados numéricos
Programas de Rastreamento/estatística & dados numéricos
Sangue Oculto
Fatores de Tempo
[Mh] Termos MeSH secundário: Idoso
Colonoscopia/estatística & dados numéricos
Neoplasias Colorretais/diagnóstico
Detecção Precoce de Câncer/métodos
Feminino
Guaiaco
Seres Humanos
Incidência
Masculino
Programas de Rastreamento/métodos
Meia-Idade
Países Baixos/epidemiologia
Projetos Piloto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9000-29-7 (Guaiac)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170831
[Lr] Data última revisão:
170831
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170510
[St] Status:MEDLINE


  2 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28296927
[Au] Autor:Goede SL; Rabeneck L; van Ballegooijen M; Zauber AG; Paszat LF; Hoch JS; Yong JH; Kroep S; Tinmouth J; Lansdorp-Vogelaar I
[Ad] Endereço:Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands.
[Ti] Título:Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.
[So] Source:PLoS One;12(3):e0172864, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The ColonCancerCheck screening program for colorectal cancer (CRC) in Ontario, Canada, is considering switching from biennial guaiac fecal occult blood test (gFOBT) screening between age 50-74 years to the more sensitive, but also less specific fecal immunochemical test (FIT). The aim of this study is to estimate whether the additional benefits of FIT screening compared to gFOBT outweigh the additional costs and harms. METHODS: We used microsimulation modeling to estimate quality adjusted life years (QALYs) gained and costs of gFOBT and FIT, compared to no screening, in a cohort of screening participants. We compared strategies with various age ranges, screening intervals, and cut-off levels for FIT. Cost-efficient strategies were determined for various levels of available colonoscopy capacity. RESULTS: Compared to no screening, biennial gFOBT screening between age 50-74 years provided 20 QALYs at a cost of CAN$200,900 per 1,000 participants, and required 17 colonoscopies per 1,000 participants per year. FIT screening was more effective and less costly. For the same level of colonoscopy requirement, biennial FIT (with a high cut-off level of 200 ng Hb/ml) between age 50-74 years provided 11 extra QALYs gained while saving CAN$333,300 per 1000 participants, compared to gFOBT. Without restrictions in colonoscopy capacity, FIT (with a low cut-off level of 50 ng Hb/ml) every year between age 45-80 years was the most cost-effective strategy providing 27 extra QALYs gained per 1000 participants, while saving CAN$448,300. INTERPRETATION: Compared to gFOBT screening, switching to FIT at a high cut-off level could increase the health benefits of a CRC screening program without considerably increasing colonoscopy demand.
[Mh] Termos MeSH primário: Neoplasias Colorretais/diagnóstico
Fezes
Sangue Oculto
[Mh] Termos MeSH secundário: Análise Custo-Benefício
Guaiaco
Seres Humanos
Imunoquímica
Qualidade de Vida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9000-29-7 (Guaiac)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170907
[Lr] Data última revisão:
170907
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0172864


  3 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28011577
[Au] Autor:Taylor M; Wood HM; Halloran SP; Quirke P
[Ad] Endereço:Section of Pathology and Tumor Biology, Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
[Ti] Título:Examining the potential use and long-term stability of guaiac faecal occult blood test cards for microbial DNA 16S rRNA sequencing.
[So] Source:J Clin Pathol;70(7):600-606, 2017 Jul.
[Is] ISSN:1472-4146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: With a growing interest in the influence the gut microbiome has on the development of colorectal cancer (CRC), we investigated the feasibility and stability of isolating and typing microbial DNA from guaiac faecal occult blood test (gFOBt) cards. This has the future potential to screen the microbial populations present in confirmed colorectal neoplasia cases with aims to predict the presence and development of CRC. METHODS: Fresh stool samples from three healthy volunteers were applied to gFOBt cards. DNA was extracted from both the cards and fresh stool samples. A series of additional cards were prepared from one volunteer, and extracted at time points between 2 weeks and 3 years. The V4 region of the 16S rRNA gene was amplified and sequenced on an Illumina MiSeq at 2×250 bp read lengths. Data were analysed using QIIME software. RESULTS: Samples were grouped both by volunteer and by type (fresh or gFOBt), and compared a variety of ways: visual inspection of taxa, α and ß diversity, intraclass correlation. In all comparisons, samples grouped by volunteer, and not by sample type. The different time points showed no appreciable differences with increased storage time. CONCLUSIONS: This study has demonstrated that there is good concordance between microbial DNA isolated from fresh stool sample, and from the matched gFOBt card. Samples stored for up to 3 years showed no detrimental effect on measureable microbial DNA. This study has important future implications for investigating microbial influence on CRC development and other pathologies.
[Mh] Termos MeSH primário: Guaiaco
Indicadores e Reagentes
Sangue Oculto
RNA Ribossômico 16S/genética
[Mh] Termos MeSH secundário: Neoplasias Colorretais/diagnóstico
DNA Bacteriano/metabolismo
Estabilidade de Medicamentos
Estudos de Viabilidade
Fezes/química
Microbioma Gastrointestinal
Voluntários Saudáveis
Seres Humanos
Análise de Sequência de RNA
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Bacterial); 0 (Indicators and Reagents); 0 (RNA, Ribosomal, 16S); 9000-29-7 (Guaiac)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161225
[St] Status:MEDLINE
[do] DOI:10.1136/jclinpath-2016-204165


  4 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27709321
[Au] Autor:Nakano Y; Nasu M; Kano M; Kameoka H; Okuyama T; Nishizawa M; Ikeya Y
[Ad] Endereço:Department of Biomedical Sciences, College of Life Sciences, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga, 525-8577, Japan.
[Ti] Título:Lignans from guaiac resin decrease nitric oxide production in interleukin 1ß-treated hepatocytes.
[So] Source:J Nat Med;71(1):190-197, 2017 Jan.
[Is] ISSN:1861-0293
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:Guaiac resin, extracted from the heartwood of Guaiacum officinale L. or G. sanctum L., is speculated to have anti-inflammatory effects. Lignans were purified from guaiac resin (also known as gum guaiacum) by monitoring the nitric oxide (NO) production in rat hepatocytes treated with an inflammatory cytokine interleukin-1ß (IL-1ß). Six lignans were purified from guaiac resin and identified as: dehydroguaiaretic acid (1), (+)-trans-1,2-dihydrodehydroguaiaretic acid (2), furoguaiaoxidin (3), meso-dihydroguaiaretic acid (4), furoguaiacin (i.e., α-guaiaconic acid) (5), and nectandrin B (6). To our knowledge, this is the first time that 1 has been isolated from guaiac resin as a non-derivative. Compounds 2 and 6 were first found in guaiac resin. Compound 3 was first isolated from a natural source as a non-derivative. Furthermore, 1-6 significantly suppressed NO production in IL-1ß-treated hepatocytes. Because anti-inflammatory compounds suppress NO production, this system is often used to measure the anti-inflammatory effects of Kampo drugs and herbal constituents. The NO-suppressing activity of the six lignans isolated in this study indicates that guaiac resin has anti-inflammatory effects and that these lignans may be responsible for the anti-inflammatory effects of guaiac resin.
[Mh] Termos MeSH primário: Guaiaco/química
Hepatócitos/efeitos dos fármacos
Interleucina-1beta/metabolismo
Lignanas/uso terapêutico
Óxido Nítrico/metabolismo
Resinas Vegetais/química
[Mh] Termos MeSH secundário: Animais
Lignanas/farmacologia
Masculino
Óxido Nítrico/biossíntese
Ratos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Interleukin-1beta); 0 (Lignans); 0 (Resins, Plant); 31C4KY9ESH (Nitric Oxide); 9000-29-7 (Guaiac)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171104
[Lr] Data última revisão:
171104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161007
[St] Status:MEDLINE
[do] DOI:10.1007/s11418-016-1048-3


  5 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27267903
[Au] Autor:Moss S; Mathews C; Day TJ; Smith S; Seaman HE; Snowball J; Halloran SP
[Ad] Endereço:Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.
[Ti] Título:Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England.
[So] Source:Gut;66(9):1631-1644, 2017 Sep.
[Is] ISSN:1468-3288
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The National Health Service Bowel Cancer Screening Programme (BCSP) in England uses a guaiac-based faecal occult blood test (gFOBt). A quantitative faecal immunochemical test (FIT) for haemoglobin (Hb) has many advantages, including being specific for blood, detecting Hb at a much lower concentration with a single faecal sample and improved uptake. METHODS: In 2014, a large comparative pilot study was performed within BCSP to establish the acceptability and diagnostic performance of FIT. Over a 6-month period, 40 930 (1 in 28) subjects were sent a FIT (OC-SENSOR) instead of a gFOBt. A bespoke FIT package was used to mail FIT sampling devices to and from FIT subjects. All participants positive with either gFOBt or FIT (cut-off 20 µg Hb/g faeces) were referred for follow-up. Subgroup analysis included cut-off concentrations, age, sex, screening history and deprivation quintile. RESULTS: While overall uptake increased by over 7 percentage points with FIT (66.4% vs 59.3%, OR 1.35, 95% CI 1.33 to 1.38), uptake by previous non-responders almost doubled (FIT 23.9% vs gFOBt 12.5%, OR 2.20, 95% CI 2.10 to 2.29). The increase in overall uptake was significantly higher in men than women and was observed across all deprivation quintiles. With the conventional 20 µg/g cut-off, FIT positivity was 7.8% and ranged from 5.7% in 59-64-year-old women to 11.1% in 70-75-year-old men. Cancer detection increased twofold and that for advanced adenomas nearly fivefold. Detection rates remained higher with FIT for advanced adenomas, even at 180 µg Hb/g. CONCLUSIONS: Markedly improved participation rates were achieved in a mature gFOBt-based national screening programme and disparities between men and women were reduced. High positivity rates, particularly in men and previous non-respondents, challenge the available colonoscopy resource, but improvements in neoplasia detection are still achievable within this limited resource.
[Mh] Termos MeSH primário: Neoplasias Colorretais
Detecção Precoce de Câncer
Sangue Oculto
Participação do Paciente/estatística & dados numéricos
[Mh] Termos MeSH secundário: Idoso
Neoplasias Colorretais/diagnóstico
Neoplasias Colorretais/epidemiologia
Neoplasias Colorretais/patologia
Detecção Precoce de Câncer/métodos
Detecção Precoce de Câncer/normas
Inglaterra/epidemiologia
Fezes
Feminino
Guaiaco/farmacologia
Hemoglobinas/análise
Seres Humanos
Imunoquímica/métodos
Masculino
Meia-Idade
Avaliação de Processos e Resultados (Cuidados de Saúde)
Projetos Piloto
Melhoria de Qualidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hemoglobins); 9000-29-7 (Guaiac)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170906
[Lr] Data última revisão:
170906
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160609
[St] Status:MEDLINE
[do] DOI:10.1136/gutjnl-2015-310691


  6 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27446842
[Au] Autor:Paszat L; Sutradhar R; Tinmouth J; Baxter N; Rabeneck L
[Ad] Endereço:Institute for Clinical Evaluative Sciences and the University of Toronto, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5.
[Ti] Título:Interval Colorectal Cancers following Guaiac Fecal Occult Blood Testing in the Ontario ColonCancerCheck Program.
[So] Source:Can J Gastroenterol Hepatol;2016:4768728, 2016.
[Is] ISSN:2291-2797
[Cp] País de publicação:Egypt
[La] Idioma:eng
[Ab] Resumo:Background. This work examines the occurrence of interval colorectal cancers (CRCs) in the Ontario ColonCancerCheck (CCC) program. We define interval CRC as CRC diagnosed within 2 years following normal guaiac fecal occult blood testing (gFOBT). Methods. Persons aged 50-74 who completed a baseline CCC gFOBT kit in 2008 and 2009, without a prior history of CRC, or recent colonoscopy, flexible sigmoidoscopy, or gFOBT, were identified. Rates of CRC following positive and normal results at baseline and subsequent gFOBT screens were computed and overall survival was compared between those following positive and normal results. Results. Interval CRC was diagnosed within 24 months following the baseline screen among 0.16% of normals and following the subsequent screen among 0.18% of normals. Interval cancers comprised 38.70% of CRC following the baseline screen and 50.86% following the subsequent screen. Adjusting for age and sex, the hazard ratio (HR) for death following interval cancer compared to CRC following positive result was 1.65 (1.32, 2.05) following the first screen and 1.71 (1.00, 2.91) following the second screen. Conclusion. Interval CRCs following gFOBT screening comprise a significant proportion of CRC diagnosed within 2 years after gFOBT testing and are associated with a higher risk of death.
[Mh] Termos MeSH primário: Neoplasias Colorretais/diagnóstico
Neoplasias Colorretais/epidemiologia
Detecção Precoce de Câncer/métodos
Programas de Rastreamento/métodos
Sangue Oculto
[Mh] Termos MeSH secundário: Idoso
Feminino
Guaiaco
Seres Humanos
Indicadores e Reagentes
Masculino
Meia-Idade
Ontário/epidemiologia
Modelos de Riscos Proporcionais
Fatores de Risco
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Indicators and Reagents); 9000-29-7 (Guaiac)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160723
[St] Status:MEDLINE
[do] DOI:10.1155/2016/4768728


  7 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27305648
[Au] Autor:Inadomi JM
[Ad] Endereço:Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, Seattle2Department of Health Services, University of Washington School of Public Health, Seattle.
[Ti] Título:Colorectal Cancer Screening: Which Test Is Best?
[So] Source:JAMA Oncol;2(8):1001-3, 2016 08 01.
[Is] ISSN:2374-2445
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Colonoscopia
Neoplasias Colorretais/diagnóstico
DNA/análise
Detecção Precoce de Câncer/métodos
Sangue Oculto
[Mh] Termos MeSH secundário: Colonografia Tomográfica Computadorizada
Guaiaco
Seres Humanos
Imunoquímica
Indicadores e Reagentes
Guias de Prática Clínica como Assunto
Sigmoidoscopia
Estados Unidos
[Pt] Tipo de publicação:EDITORIAL
[Nm] Nome de substância:
0 (Indicators and Reagents); 9000-29-7 (Guaiac); 9007-49-2 (DNA)
[Em] Mês de entrada:1701
[Cu] Atualização por classe:170130
[Lr] Data última revisão:
170130
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160616
[St] Status:MEDLINE
[do] DOI:10.1001/jamaoncol.2016.2494


  8 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27135192
[Au] Autor:Cooper JA; Moss SM; Smith S; Seaman HE; Taylor-Phillips S; Parsons N; Halloran SP
[Ad] Endereço:Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry, UK. jennifer.cooper@warwick.ac.uk.
[Ti] Título:FIT for the future: a case for risk-based colorectal cancer screening using the faecal immunochemical test.
[So] Source:Colorectal Dis;18(7):650-3, 2016 Jul.
[Is] ISSN:1463-1318
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Worldwide, the guaiac faecal occult blood test (gFOBT) is being replaced with the more accurate faecal immunochemical test (FIT) for colorectal cancer (CRC) screening. From January 2016, the National Screening Committee in the UK has recommended a change from the gFOBT to the FIT following a successful Bowel Cancer Screening Programme pilot study with over 40 000 participants. Although the test has shown improved uptake and the ability to detect significantly more colorectal cancers and advanced adenomas, the higher uptake and test positivity will challenge the capacity of colonoscopy services. One of the main advantages of the FIT is that it provides a quantitative haemoglobin concentration which has been shown to relate to the risk of CRC. Risk scoring systems which combine the FIT concentration with risk factor assessment have been shown to improve the sensitivity of the test. This individualized approach to screening could enable those at greatest risk to be referred for colonoscopy, optimizing resource use and ultimately patient outcomes.
[Mh] Termos MeSH primário: Neoplasias Colorretais/diagnóstico
Detecção Precoce de Câncer/tendências
Fezes/química
Previsões
Programas de Rastreamento/tendências
[Mh] Termos MeSH secundário: Detecção Precoce de Câncer/métodos
Guaiaco
Seres Humanos
Programas de Rastreamento/métodos
Sangue Oculto
Valor Preditivo dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9000-29-7 (Guaiac)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160503
[St] Status:MEDLINE
[do] DOI:10.1111/codi.13365


  9 / 308 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26858128
[Au] Autor:Hirai HW; Tsoi KK; Chan JY; Wong SH; Ching JY; Wong MC; Wu JC; Chan FK; Sung JJ; Ng SC
[Ad] Endereço:School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, Hong Kong.
[Ti] Título:Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.
[So] Source:Aliment Pharmacol Ther;43(7):755-64, 2016 Apr.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The performance of faecal occult blood tests (FOBTs) to screen proximally located colorectal cancer (CRC) has produced inconsistent results. AIM: To assess in a meta-analysis, the diagnostic accuracy of FOBTs for relative detection of CRC according to anatomical location of CRC. METHODS: Diagnostic studies including both symptomatic and asymptomatic cohorts assessing performance of FOBTs for CRC were searched from MEDINE and EMBASE. Primary outcome was accuracy of FOBTs according to the anatomical location of CRC. Bivariate random-effects model was used. Subgroup analyses were performed to evaluate test performance of guaiac-based FOBT (gFOBT) and immunochemical-based FOBT (iFOBT). RESULTS: Thirteen studies, with 17 cohorts, reporting performance of FOBT were included; a total of 26 342 patients (mean age 58.9 years; 58.1% male) underwent both colonoscopy and FOBT. Pooled sensitivity, specificity, positive likelihood ratio and negative likelihood ratio of FOBTs for CRC detection in the proximal colon were 71.2% (95% CI 61.3-79.4%), 93.6% (95% CI 90.7-95.7%), 11.1 (95% CI 7.8-15.8) and 0.3 (95% CI 0.2-0.4) respectively. Corresponding findings for CRC detection in distal colon were 80.1% (95% CI 70.9-87.0%), 93.6% (95% CI 90.7-95.7%), 12.6 (95% CI 8.8-18.1) and 0.2 (95% CI 0.1-0.3). The area-under-curve for FOBT detection for proximal and distal CRC were 90% vs. 94% (P = 0.0143). Both gFOBT and iFOBT showed significantly lower sensitivity but comparable specificity for the detection of proximally located CRC compared with distal CRC. CONCLUSION: Faecal occult blood tests, both guaiac- and immunochemical-based, show better diagnostic performance for the relative detection of colorectal cancer in the distal colon than in the proximal bowel.
[Mh] Termos MeSH primário: Colo/patologia
Colonoscopia/normas
Neoplasias Colorretais/diagnóstico
Detecção Precoce de Câncer/normas
Sangue Oculto
[Mh] Termos MeSH secundário: Idoso
Estudos de Coortes
Colonoscopia/métodos
Neoplasias Colorretais/sangue
Detecção Precoce de Câncer/métodos
Feminino
Guaiaco/análise
Seres Humanos
Masculino
Meia-Idade
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
9000-29-7 (Guaiac)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160210
[St] Status:MEDLINE
[do] DOI:10.1111/apt.13556


  10 / 308 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26651256
[Au] Autor:Chiu HM; Chang LC; Hsu WF; Chou CK; Wu MS
[Ad] Endereço:Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Health Management Center, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: hanmochiu@ntu.edu.tw.
[Ti] Título:Non-invasive screening for colorectal cancer in Asia.
[So] Source:Best Pract Res Clin Gastroenterol;29(6):953-65, 2015 Dec.
[Is] ISSN:1532-1916
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:There is an increasing trend of colorectal cancer incidence in Asia and nearly 45% of CRC cases worldwide occur in Asia therefore screening for CRC becomes an urgent task. Stool-based tests, including guaiac fecal occult blood test (gFOBT) and fecal immunochemical test (FIT), can select subjects at risk of significant colorectal neoplasms from the large target population thus are currently the most commonly used non-invasive screening tool in large population screening programs. FIT has the advantage over gFOBT in terms of higher sensitivity for early neoplasms, the ability to provide high-throughput automatic analysis, and better public acceptance thus greater effectiveness on reducing CRC mortality and incidence is expected. Owing to the large target population and constrained endoscopic capacity and manpower, FIT is nowadays the most popular CRC screening test in Asia. Some Asian countries have launched nationwide screening program in the past one or two decades but also encountered some challenges such as low screening participation rate, low verification rate after positive stool tests, low public awareness, and insufficient manpower. In addition, some controversial or potential future research issues are also addressed in this review.
[Mh] Termos MeSH primário: Neoplasias Colorretais/diagnóstico
Guaiaco
Indicadores e Reagentes
Programas de Rastreamento/métodos
Sangue Oculto
[Mh] Termos MeSH secundário: Ásia/epidemiologia
Neoplasias Colorretais/epidemiologia
Neoplasias Colorretais/prevenção & controle
Fezes
Seres Humanos
Incidência
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Indicators and Reagents); 9000-29-7 (Guaiac)
[Em] Mês de entrada:1605
[Cu] Atualização por classe:151215
[Lr] Data última revisão:
151215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151215
[St] Status:MEDLINE



página 1 de 31 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde